Chemomab Therapeutics Ltd.
corporate_fare Company Profile
Chemomab Therapeutics Ltd. (NASDAQ:CMMB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for CMMB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for CMMB spans SCHEDULE 13D, DEFA14A, DEFM14A, 6-K.
Recent high-impact activity:
- Scipher Discloses 10.4% Chemomab Stake After $1.1M Note-Funded ADS Purchase
- Chemomab Supplement Discloses $1.1M Scipher ATM Purchase and Updated Merger Exchange Ratio
- Chemomab Sets Dec 4 Vote on Scipher Merger; Holders Get 32% of Combined Company
- Chemomab Halves Combined-Company Share Count to 5M in Merger Amendment No. 2
- Chemomab Amends Merger Agreement to Set 10M-Share Post-Merger Structure
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 5,139 shares in CMMB as of the October 30, 2026 settlement, a 63.0% decrease from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 57.1% of CMMB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
CMMB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.